<DOC>
	<DOC>NCT00232687</DOC>
	<brief_summary>The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.</brief_summary>
	<brief_title>A Switch Study of BMS-337039 in Schizophrenic Out-patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients with a diagnosis of schizophrenia as defined by DSMIVTR2 criteria Outpatients who have been taking Risperidone for minimum 6 weeks who are not optimally controlled and/or experiencing safety/tolerability issues with Risperidone Men and women, aged 18 65 years Patients who are at risk for committing suicide Patients with a diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic symptoms, or organic brain syndromes Meeting DSMIVTR criteria for any significant Psychoactive Substance Use Disorder within the 3 months prior to Screening Treatmentresistant to antipsychotic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>